glp-1 receptor agonist antipsychotic weight gain study Efficacy and Safety of Agonists for the Management of Antipsychotic-Induced Rank order of liability for
Description
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Oral semaglutide has been approved and recently marketed in Spain following evidence from the Phase 3 clinical trial program Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
Mol Metab 2019;30:72130
h - m , GLP-1MK-801 corrects body weight and fat mass relative to age-matched chow-fed control mice
10.1016/j.nefro.2022.07.008 [DOI] [PubMed] [Google Scholar] 27
